(Nasdaq: ALNY), a leading RNAi therapeutics company, is presenting new today from its GalNAc-conjugate siRNA programs for the systemic delivery of RNAi therapeutics at the XX International Roundtable ...
KAWASAKI, Japan, December 18, 2025--(BUSINESS WIRE)--PeptiDream Inc., a public Japan-based biopharmaceutical company (President: Patrick C. Reid, hereinafter "PeptiDream")(Tokyo: 4587), announced the ...
In this free webinar, learn about conjugation methods, applications and clinical progress of small nucleic acid drug conjugates. Attendees will gain insight into the characterization of conjugated ...
New York, USA – December 29, 2022 – BOC Sciences today announced the release of premium GalNAc-siRNA conjugation services to further support the delivery of siRNA drugs to the liver.
PHILADELPHIA--(BUSINESS WIRE)--Aro Biotherapeutics, a biotechnology company pioneering the development of tissue-targeted genetic medicines, today announced upcoming data presentations highlighting ...
PHILADELPHIA--(BUSINESS WIRE)--Aro Biotherapeutics, a clinical stage biotechnology company pioneering the development of tissue-targeted genetic medicines, today announced upcoming data presentations ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that the Company presented new pre-clinical data highlighting its ...
– New Pre-clinical Data from 'Alnylam5x15' Programs Including ALN-TTRsc for the Treatment of Transthyretin-Mediated Amyloidosis (ATTR) and ALN-AT3 for the Treatment of Hemophilia – CAMBRIDGE, ...
Results of recent studies demonstrate that Aro’s muscle-targeted Centyrin-siRNA conjugate robustly reduces toxic accumulation of muscle glycogen in a murine model of Pompe disease Presentation and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results